We return to the topic of dyslipidemia and examined the: “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults” http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a

Previous episodes on statins can be found here.

Major differences between AHA 2013 guideline and CCS 2012 guideline:

• 
  
• LR (FRS<10%): consider lifestyle only
  
• IR (FRS 10-19%), if LDL <3.5mmol/L: consider lifestyle only
  
• Optional alternate target and secondary tests reasonable
  
• HR (FRS >20%), history of CVD, DM aged >40: statins
  
• LDL >5 mmol/L: statins
  

• 
  
• CVD: statins
  
• LDL > 4.9 mmol/L: statins
  
• DM aged 40-75: statins
  
• 10-year risk >7.5%: statins
  

• 
  
• LDL >50% reduction
  
• LDL < 2mmol/L for IR and HR groups
  

• 
  
• No target
  
• Fixed dose statins based on initial risk assessment
  

Pooled Cohort Equations to estimate 10-year CVD risk: http://www.cardiosource.org/science-and-quality/practice-guidelines-and-quality-standards/2013-prevention-guideline-tools.aspx

Dr. McCormack’s discussion on patient centered EBM on KevinMD: http://www.kevinmd.com/blog/2013/12/cholesterol-guidelines-emphasize-patient-preference.html

The post Dyslipidemia 3: AHA 2013 Guideline appeared first on Family Pharm Podcast.